Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Jane Street Group LLC cut its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 96.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,977 shares of the company's stock after selling 318,465 shares during the period. Jane Street Group LLC's holdings in Stoke Therapeutics were worth $132,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in Stoke Therapeutics by 29.2% in the fourth quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock worth $220,000 after acquiring an additional 4,512 shares during the period. Renaissance Technologies LLC bought a new position in Stoke Therapeutics in the fourth quarter worth approximately $1,423,000. Bank of New York Mellon Corp raised its position in Stoke Therapeutics by 1.4% in the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock worth $1,028,000 after acquiring an additional 1,330 shares during the period. Rhumbline Advisers increased its stake in shares of Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock worth $545,000 after purchasing an additional 2,787 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics in the fourth quarter worth $113,000.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 6,471 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the transaction, the insider now owns 25,782 shares of the company's stock, valued at $258,593.46. This trade represents a 20.06% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,748 shares of company stock valued at $225,687. Corporate insiders own 11.30% of the company's stock.

Stoke Therapeutics Stock Performance

STOK opened at $11.14 on Friday. The stock has a market capitalization of $608.21 million, a price-to-earnings ratio of -5.30 and a beta of 1.09. The company has a fifty day moving average of $8.77 and a 200 day moving average of $9.65. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on STOK shares. Chardan Capital reissued a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright reduced their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and an average target price of $23.20.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.